Publications by authors named "Carisa Deanda"
Tedizolid (TR-700, formerly torezolid) is the active moiety of the prodrug tedizolid phosphate (TR-701), a next-generation oxazolidinone, with high potency against Gram-positive species, including methicillin-resistant Staphylococcus aureus (MRSA). A recently completed randomized, double-blind phase 2 trial evaluated 200, 300, or 400 mg of oral tedizolid phosphate once daily for 5 to 7 days in patients with complicated skin and skin structure infections. This report examines the in vitro activity of tedizolid and Zyvox (linezolid) against Gram-positive pathogens isolated at baseline and describes the microbiological and clinical efficacy of tedizolid.
View Article and Find Full Text PDFArticle Synopsis
- Plasma concentrations of antimicrobial drugs are often used to connect drug exposure with effects, but unbound concentrations in plasma and tissues might differ; understanding unbound tissue concentrations is crucial for antimicrobial drug development.
- A clinical microdialysis study investigated the distribution of tedizolid, an antimicrobial drug, in subcutaneous adipose and skeletal muscle tissues after a single oral dose in 12 healthy adults, using probes implanted in their thighs.
- Results showed that unbound tedizolid levels in plasma were similar to those in adipose and muscle tissues, indicating effective distribution, with well-correlated free plasma levels influencing tissue concentrations, and overall the drug was well tolerated.